Articles tagged with Drug Studies
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
A single dose of a psychedelic compound can enhance cognitive flexibility for weeks after administration, according to a groundbreaking study. Mice treated with the compound showed improved performance in reversal learning tasks compared to control groups when tested weeks later.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
A new oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, Orforglipron, has demonstrated significant weight loss of 7.9% in individuals with diabetes and impaired glycemic control. The safety and tolerability of the medication are consistent with injectable therapies, making it a potentially accessible treatment option.
Adding an experimental cancer drug to standard TB treatment reduces lung damage and prevents post-TB lung disease in mice. Researchers found that the drug doubled pulmonary apoptosis and reduced lung scarring by 40% compared to standard treatments.
A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.
Researchers have identified a combination of drugs that prevents enteroviruses from replicating, which could lead to an effective treatment for global health problem. The combination includes pleconaril, AG7404, and mindeudesivir, which shows great potential for finding broad-spectrum treatment methods against enteroviruses.
Researchers investigated the neuroregenerative potential of 5-NOT and Epi, discovering they protected SH-SY5Y cells from MPP+ toxicity by regulating key proteins. The findings support 5-NOT as a glycomimetic drug candidate for Parkinson's disease treatment.
Researchers have initiated a clinical trial using an investigational medicine to lower amyloid precursor protein, targeting Alzheimer's disease in adults with Down syndrome. The study aims to prevent the development of Alzheimer's disease by addressing its underlying genetic cause.
A new study published in Brain Medicine found that administering Osanetant shortly after a traumatic event significantly dampens fear expression in female mice. This suggests that targeting fear memory at its roots may be an effective intervention to reduce PTSD-like behaviors.
A new Northwestern University study finds that NU-9 improves neuron health in animal models of Alzheimer's disease by addressing the underlying mechanisms of misfolded proteins. The drug reduces protein buildup and prevents inflammation, showing potential for treating neurodegenerative diseases.
A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
The European HTA agencies and EMA have developed joint positions to address methodological challenges in assessing new drugs. Key findings include the need for randomized controlled trials and flexible study designs that can reduce sample size requirements and development timeframes.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
A new clinical trial found that oral semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and pre-existing cardiovascular disease. The medication decreased the risk of major cardiac events by 14% compared to placebo, with nonfatal myocardial infarction seeing the greatest reductions in risk.
A new antidote, bentracimab, safely restored platelet function in patients on ticagrelor, reducing the risk of bleeding during urgent surgery or major bleeding events. The study showed similar results for surgical and bleeding patients, with 94.3% achieving normal blood clotting after treatment.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A new study found that three months of dual antiplatelet therapy (DAPT) was better than one month for reducing heart attacks, strokes, and other adverse events without increasing bleeding risk in high-risk patients. For low-risk patients, three months of DAPT was comparable to 12 months in reducing adverse events, while being better th...
A Phase 2b trial found lorundrostat significantly reduced blood pressure in patients with uncontrolled hypertension by 7.9 mm Hg and 6.5 mm Hg compared to placebo at 12 weeks. The drug showed an acceptable side effect profile, with consistent patterns across secondary endpoints.
A study found that semaglutide significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes. Patients taking semaglutide also experienced improvements in symptoms and quality of life compared to those on a placebo.
Researchers have studied the mechanism of action of bioactive compounds from papaya, passion fruit, and medicinal plant extracts. Modified pectins extracted from these plants show potential as supplements or food ingredients to boost biological activity against colon cancer and gut microbiota.
Researchers propose GLDH as a more liver-specific biomarker for detecting liver injury, offering greater specificity than current ALT and AST tests. The test performed similarly to ALT for detecting liver injury but was not impacted by associated muscle injury.
The C-Path-led initiative brought together clinical trial sponsors, eCOA technology providers, and regulators to identify and address eCOA implementation issues. Key resources developed during the initiative include guidance on COA data collection and a more open, collaborative environment.
A UniSA-led study is trialing medication safety rounds in aged care homes to identify and address potential problems with medication use. The project aims to reduce medication-induced harm and improve residents' health and wellbeing through pharmacist-led safety rounds, adapting an existing palliative care need rounds model.
The FDA has approved cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors. The drug showed improved efficacy in reducing tumor growth and improving patient survival compared to placebo.
Researchers at UW–Madison have discovered that the arthritis drug tofacitinib can halt brain-damaging seizures in mice, restore short-term memory, and reduce inflammation. The drug has shown promising results in preventing seizures even after treatment is stopped, offering a potential new approach for treating epilepsy.
A large study suggests that patients at high risk of heart attacks and strokes should be treated immediately with a combination of a statin and ezetimibe, rather than statins alone. This combination therapy significantly reduces the risk of death from any cause and major adverse cardiovascular events.
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
Researchers found that digital games effective in reducing drinking, smoking, and illicit drug use among adolescents when personalized to individual players, had social components, and included content encouraging behavior change.
A clinical trial shows that removing amyloid plaques from the brain can delay Alzheimer's symptoms, supporting the amyloid hypothesis. The treatment reduced the risk of developing dementia in people destined to develop early-onset Alzheimer's disease.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
The ASCOLT trial found that aspirin does not statistically improve disease-free survival for all patients but demonstrates a consistent trend of improving overall and disease-free survival. Aspirin taken for up to 3 years is efficacious in patients with PIK3CA mutation, reducing recurrence by over 50%.
Researchers at NIH identified characteristic symptoms of topical steroid withdrawal (TSW), including elevated nicotinamide adenine dinucleotide (NAD+) levels, which can be diagnosed using provisional criteria. TSW treatment may involve mitochondrial complex I-blocking drugs, such as metformin or berberine.
Researchers have discovered a new diterpene-based drug that facilitates the repopulation of mature functional neurons in brain regions damaged by traumatic injuries. The study found that these new cells are integrated into neural circuits and develop functional characteristics similar to those eliminated by the injury.
Researchers found that mobile units with peer navigation improved health outcomes for participants with opioid use disorder, with about seven percent on medication and 35 percent virally suppressed. The study also showed lower odds of all-cause mortality in the intervention arm.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control. The antiviral drug was shown to be safe but ineffective in treating clade II mpox.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
Researchers are conducting a first-in-human clinical trial to test a modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder. The therapy, EG110A, aims to block sensory nerve signals causing involuntary bladder contractions and incontinence.
Scientists at Sanford Burnham Prebys discovered novel fragments of future drugs that selectively inhibit the enzyme VHR, which plays a role in controlling the immune system's response to danger. The findings may lead to the development of new therapies for sepsis and septic shock.
A new study found that Black Americans are more willing to participate in medical studies led by Black doctors and researchers. Diversifying clinical trial leadership could improve enrollment of underrepresented groups and ensure the benefits and risks of treatments are understood across populations.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
Eradivir's EV25 is a small molecule immunotherapy biotech company developing treatments for influenza. The Phase 2 challenge study will gather safety and efficacy data from healthy participants infected with influenza.
A new study analyzing health records from 2012 to 2022 found significant differences in cardiovascular disease risk factors among Asian American, Native Hawaiian, and Pacific Islander populations. The research suggests that regular monitoring of risk factors may help prevent cardiovascular disease among these groups.
Researchers are conducting a clinical trial to find the optimal combination of pain management tools for patients undergoing mastectomy procedures. The study will enroll approximately 100 patients and examine various combinations of pectoralis nerve blocks, non-opioid analgesics, and administration methods.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
Researchers at the University of Missouri have identified a small molecule drug that targets a specific serotonin receptor, showing promise as a treatment for sarcopenia. The study suggests that this neurotherapeutic can improve muscle strength by activating motor neurons to fire more effectively.
The March issues of The American Journal of Psychiatry and Psychiatric Services bring together new developments in treating depression, obsessive-compulsive disorder, and schizophrenia. These journal publications highlight the latest advancements in digital mental health innovations.
The Texas Tech University Health Sciences Center is conducting a randomized controlled trial to investigate the effectiveness of calcium and vasopressin in treating severely injured patients who experience significant blood loss. The study, known as CAVALIER, will enroll approximately 1,050 participants aged 18-90.
A new study found that nearly 20% of cancer patients in middle-stage drug trials receive treatment that later gets FDA approval. This has important implications for drug development and clinical trial recruitment.
Researchers explore ataciguat to manage aortic valve stenosis, showing potential to significantly slow disease progression. The drug may enable a once-in-a-lifetime procedure by delaying valve replacement surgery.
US outpatient prescriptions for ivermectin and hydroxychloroquine increased significantly during the COVID-19 pandemic, with usage being three times higher among adults aged 65 and older. The study's findings highlight the need for policy reforms to combat misinformation and mistrust in scientific institutions.
Research found that community-dwelling older adults with advanced age, frailty, or multiple prescription medications had greater net benefits from intensive blood pressure lowering. However, this approach can increase treatment-related harms in these groups.
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa, a group of rare and severe skin disorders. The licensing agreement includes collaboration with Theravia to develop, register and commercialise the drug.
A new study found that generic drugs made in India have significantly more 'severe adverse events' for patients, including hospitalization and death. The researchers matched 2,443 drugs made in the US and emerging economies, finding that mature generic drugs were responsible for the higher rates of severe adverse events.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.